|
||
Aknemycin 20mg/g Pregnancy |
||
Aknemycin 20mg/g crosses the placenta in small amounts. In one study of 11 patients who had detectable Aknemycin 20mg/g levels in the serum, 4 infants did not have detectable cord concentrations. The cord concentrations in the remaining 7 infants generally ranged from 1% to 6% of that found in maternal serum. A case of left absence-of-tibia syndrome was reported in an infant whose mother had received Aknemycin 20mg/g, ethisterone, and ethinyl estradiol at approximately 4 weeks gestation. Aknemycin 20mg/g has been used prior to delivery in women colonized with group B beta-hemolytic streptococcus to reduce infant colonization. No adverse events in the infants have been reported. Aknemycin 20mg/g has also been used to treat genital Mycoplasma infection during the first trimester without evidence of fetal adverse effects. Pregnant women receiving Aknemycin 20mg/g estolate may be more prone to hepatotoxicity. In one study of women receiving Aknemycin 20mg/g estolate between the 22nd and 32nd week of pregnancy, 10% showed abnormal levels of SGOT.
Aknemycin 20mg/g has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. The Centers for Disease Control and Prevention considers Aknemycin 20mg/g the drug of choice for treatment of Chlamydia infections in pregnant women. However, Aknemycin 20mg/g estolate is considered contraindicated because of drug-related hepatotoxicity. Aknemycin 20mg/g should only be given during pregnancy when need has been clearly established.
See references
Aknemycin 20mg/g is excreted into human milk in small amounts. Aknemycin 20mg/g is considered compatible with breast-feeding by the American Academy of Pediatrics.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|